Evolving roles of CD38 metabolism in solid tumour microenvironment
Cet article analyse le rôle, dans le microenvironnement des tumeurs solides, des métabolites associés à la protéine transmembranaire CD38 puis examine l'intérêt de cibler les voies de signalisation CD38-NAD+ ou CD38-cADPR/ADPR pour enrayer le développement tumoral
Given that plenty of clinical findings and reviews have already explained in detail on the progression of CD38 in multiple myeloma and haematological system tumours, here we no longer give unnecessary discussion on the above progression. Though therapeutic antibodies have been regarded as a greatest breakthrough in multiple myeloma immunotherapies due to the durable anti-tumour responses in the clinic, but the role of CD38 in the immunologic regulation and evasion of non-hematopoietic solid tumours are just initiated and controversial. Therefore, we will focus on the bio-function of CD38 enzymatic substrates or metabolites in the variety of non-hematopoietic malignancies and the potential therapeutic value of targeting the CD38-NAD+ or CD38-cADPR/ADPR signal axis. Though limited, we review some ongoing researches and clinical trials on therapeutic approaches in solid tumour as well.
British Journal of Cancer , résumé, 2022